This episode of Currently Speaking dives into why rapid-result oral fluid testing is gaining traction, how solutions like OralTox® and OT-Scan® are improving efficiency and compliance, and what these advancements mean for employers navigating today’s hiring challenges.

The landscape of drug testing is rapidly evolving, and organizations must adapt to remain compliant and efficient. Rod Weis's insights provide a roadmap for leveraging instant oral fluid testing, embracing full-service providers, and utilizing technology to enhance drug testing processes. By implementing these strategies, organizations can not only streamline their drug testing procedures but also ensure accuracy and compliance.

In this episode of Currently Speaking, Bill Current follows up on his recent Current in 30 webinar, Addressing Marijuana in Your Drug Testing Policy: Complacency Is Not an Option, by answering several important questions that employers frequently ask about marijuana and workplace drug testing.

As marijuana legalization continues to expand across the United States, employers are facing new challenges when it comes to maintaining safe and compliant workplaces. In this short episode, Bill discusses whether employers can still test for marijuana in states where it is legal, how companies can address workplace impairment, the risks of removing marijuana from a drug testing panel, and how often drug testing policies should be reviewed and updated.

Bill also explores the growing role of oral fluid testing and whether it can help identify more recent marijuana use compared to traditional urine testing.

If you would like to watch the full webinar presentation, a link to the recording is included with this episode. https://youtu.be/-Nv6DTGmXLs

In this episode of Currently Speaking, Bill Current discusses the evolving conversation around marijuana legalization, particularly in light of a recent editorial from the New York Times that acknowledges the negative consequences of looser marijuana policies. The discussion covers the implications of marijuana reclassification, the rise in usage and addiction, and the impact on workplace safety. Current emphasizes the need for employers to take a firm stance on marijuana use in the workplace, especially as the cannabis industry continues to grow and the realities of marijuana's effects become more apparent.

President Trump’s recent Executive Order to reclassify marijuana from a Schedule I to a Schedule III drug under the Drug Enforcement Administration has sparked debate about the future of workplace drug testing. Schedule I drugs are defined as having no accepted medical use and a high potential for abuse, while Schedule III drugs are considered to have a lower potential for dependence.Despite possible reclassification, most employers conduct drug testing primarily to promote workplace safety — the top reason cited in Current Consulting Group’s 2025 employer survey. Employers also report improved employee quality, reduced legal risks, and enhanced productivity as key benefits. Research showing high rates of on-the-job marijuana use, along with increased workers’ compensation claims in states with recreational marijuana laws, reinforces employer concerns about impairment and safety.Listen to the latest episode of Currently Speaking to learn more about how rescheduling marijuana will impact drug testing in 2026.

In Part 2 of this conversation, Bill Current and Greg Henderson dive into the FAA foreign repair station drug and alcohol testing ruling, what it requires, and why employers should act now ahead of the 2027 enforcement deadline. The discussion covers compliance timelines, waiver challenges, safety considerations, and how marijuana rescheduling may intersect with FAA testing requirements.

The conversation around marijuana rescheduling is heating up! In this podcast episode, part 1 of a 2-part series, Bill Current, founder of Current Consulting Group, and Greg Henderson, founder of Federal Drug Testing Services, dive into marijuana rescheduling, common compliance misconceptions, and what employers need to know about workplace drug testing regulations. The discussion focuses on safety, federal oversight, and why current testing requirements remain in place. Don't let misinformation steer your decisions! What questions do you have about compliance and safety in this evolving landscape? Let's chat!

As more employers remove marijuana from drug-testing panels, is it a costly mistake? According to Current Consulting Group’s 2025 Employer Drug Testing Survey, fewer companies are testing for cannabis—despite warnings from medical expert Dr. Marc Siegel, who calls marijuana “the most dangerous drug in America.”

In this episode of Currently Speaking, the podcast of the Current Consulting Group, we examine why marijuana is being normalized, the myths around its safety and medicinal value, and what employers may be overlooking about its real risks. A must-listen for business leaders, HR professionals, and anyone questioning whether weed is truly harmless.

In this episode of Currently Speaking, we dive deep into the key findings of Current Consulting Group’s 2025 Employer Drug Testing Survey—one of the industry’s most trusted sources for workplace drug testing insights.

Join us as we break down what employers are learning about the effectiveness of drug testing, emerging workplace trends, and how evolving policies, substances, and testing technologies are shaping drug-free workplace programs in 2025.

Whether you’re an HR professional, safety manager, compliance officer, or employer overseeing workforce risk management, this episode delivers actionable takeaways on:

- The most effective workplace drug testing methods in 2025

- How employers are adapting to changes in marijuana laws and impairment concerns

- Drug testing program ROI and employer-reported outcomes

- Trends in random testing, pre-employment screening, and oral fluid testing

- What the 2025 data reveals about workforce safety, productivity, and compliance